Rutger Verbeek1, Federico Oldoni2, R Preethi Surendran1, Ailko H Zwinderman3, Kay T Khaw4, Erik S G Stroes1, Nick J Wareham5, S Matthijs Boekholdt6, Geesje M Dallinga-Thie7. 1. Departments of Vascular Medicine and Experimental Vascular Medicine, Amsterdam University Medical Center, Location Academic Medical Center, Amsterdam, the Netherlands. 2. Department of Pediatrics, Section of Molecular Genetics, University Medical Center Groningen, Groningen, the Netherlands. 3. Department of Biostatistics, Amsterdam University Medical Center, Location Academic Medical Center, Amsterdam, the Netherlands. 4. Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom. 5. Medical Research Council Epidemiology Unit, Cambridge, United Kingdom. 6. Department of Cardiology, Amsterdam University Medical Center, Location Academic Medical Center, Amsterdam, the Netherlands. 7. Departments of Vascular Medicine and Experimental Vascular Medicine, Amsterdam University Medical Center, Location Academic Medical Center, Amsterdam, the Netherlands. Electronic address: g.m.dallinga@amc.nl.
Abstract
BACKGROUND: Evidence on the causal link between plasma triglyceride (TG) levels and risk for cardiovascular disease (CVD) has recently emerged. Individuals with the metabolic syndrome have an increased risk for acquiring elevated TG levels later in life. Moreover, common DNA sequence variations in genes affecting TG levels identify individuals at risk for elevated plasma TG levels. OBJECTIVE: We evaluated whether a 3-single nucleotide polymorphism (SNP) TG gene risk score (GRS) and a metabolic risk score (MetRS) both improved CVD risk prediction. METHODS: A 3-SNP GRS and MetRS were generated in the EPIC-Norfolk cohort (n = 20,074) based on 3 SNPs in LPL and APOA5 or the number of Metabolic Syndrome criteria present (maximum 5), respectively. The associations between the 3-SNP GRS, MetRS, TG levels, and CVD risk were evaluated. RESULTS: The 3-SNP GRS and MetRS were both linearly associated with plasma TG levels, that is, +0.25 mmol/L [95% CI 0.22-0.27] per allele change (P < .001) and +0.72 mmol/L [95% CI 0.70-0.73] per increase of number of metabolic syndrome risk score points (P < .001), respectively. We observed a positive association between the 3-SNP GRS and the risk of CVD with an adjusted hazard ratio (HR) of 1.35 [95% CI 1.04-1.74] for the highest versus the lowest GRS, which was independent of the MetRS. For the MetRS, the adjusted HR was 2.03 [95% CI 1.73-2.40] for the highest versus the lowest MetRS. CONCLUSION: Both the 3-SNP GRS and the MetRS are associated with increased plasma TG levels and increased risk for CVD.
BACKGROUND: Evidence on the causal link between plasma triglyceride (TG) levels and risk for cardiovascular disease (CVD) has recently emerged. Individuals with the metabolic syndrome have an increased risk for acquiring elevated TG levels later in life. Moreover, common DNA sequence variations in genes affecting TG levels identify individuals at risk for elevated plasma TG levels. OBJECTIVE: We evaluated whether a 3-single nucleotide polymorphism (SNP) TG gene risk score (GRS) and a metabolic risk score (MetRS) both improved CVD risk prediction. METHODS: A 3-SNP GRS and MetRS were generated in the EPIC-Norfolk cohort (n = 20,074) based on 3 SNPs in LPL and APOA5 or the number of Metabolic Syndrome criteria present (maximum 5), respectively. The associations between the 3-SNP GRS, MetRS, TG levels, and CVD risk were evaluated. RESULTS: The 3-SNP GRS and MetRS were both linearly associated with plasma TG levels, that is, +0.25 mmol/L [95% CI 0.22-0.27] per allele change (P < .001) and +0.72 mmol/L [95% CI 0.70-0.73] per increase of number of metabolic syndrome risk score points (P < .001), respectively. We observed a positive association between the 3-SNP GRS and the risk of CVD with an adjusted hazard ratio (HR) of 1.35 [95% CI 1.04-1.74] for the highest versus the lowest GRS, which was independent of the MetRS. For the MetRS, the adjusted HR was 2.03 [95% CI 1.73-2.40] for the highest versus the lowest MetRS. CONCLUSION: Both the 3-SNP GRS and the MetRS are associated with increased plasma TG levels and increased risk for CVD.
Authors: Brian A Ference; Wonsuk Yoo; Issa Alesh; Nitin Mahajan; Karolina K Mirowska; Abhishek Mewada; Joel Kahn; Luis Afonso; Kim Allan Williams; John M Flack Journal: J Am Coll Cardiol Date: 2012-10-17 Impact factor: 24.094
Authors: Nadeem Sarwar; Manjinder S Sandhu; Sally L Ricketts; Adam S Butterworth; Emanuele Di Angelantonio; S Matthijs Boekholdt; Willem Ouwehand; Hugh Watkins; Nilesh J Samani; Danish Saleheen; Debbie Lawlor; Muredach P Reilly; Aroon D Hingorani; Philippa J Talmud; John Danesh Journal: Lancet Date: 2010-05-08 Impact factor: 79.321
Authors: Daniel Gaudet; Veronica J Alexander; Brenda F Baker; Diane Brisson; Karine Tremblay; Walter Singleton; Richard S Geary; Steven G Hughes; Nicholas J Viney; Mark J Graham; Rosanne M Crooke; Joseph L Witztum; John D Brunzell; John J P Kastelein Journal: N Engl J Med Date: 2015-07-30 Impact factor: 91.245
Authors: Antonio J Vallejo-Vaz; Rana Fayyad; S Matthijs Boekholdt; G Kees Hovingh; John J Kastelein; Shari Melamed; Philip Barter; David D Waters; Kausik K Ray Journal: Circulation Date: 2018-08-21 Impact factor: 29.690
Authors: Stefan F C Vaessen; Frank G Schaap; Jan-Albert Kuivenhoven; Albert K Groen; Barbara A Hutten; S Matthijs Boekholdt; Hiroaki Hattori; Manjinder S Sandhu; Sheila A Bingham; Robert Luben; Jutta A Palmen; Nicholas J Wareham; Steve E Humphries; John J P Kastelein; Philippa J Talmud; Kay-Tee Khaw Journal: J Lipid Res Date: 2006-06-12 Impact factor: 5.922
Authors: Wim A van der Steeg; S Matthijs Boekholdt; Evan A Stein; Karim El-Harchaoui; Erik S G Stroes; Manjinder S Sandhu; Nicholas J Wareham; J Wouter Jukema; Robert Luben; Aeilko H Zwinderman; John J P Kastelein; Kay-Tee Khaw Journal: Ann Intern Med Date: 2007-05-01 Impact factor: 25.391